| [1] |
Integrated Chinese and Western Medicine Ovarian Cancer Specialty Committee of China Anti-Cancer Association.
China expert consensus on diagnosis and treatment of low-grade serous ovarian cancer (2024 edition)
[J]. Chinese Journal of Oncology Prevention and Treatment, 2025, 17(1): 11-20.
|
| [2] |
LU Tingting, SHI Lijun, LIU Yingzhao, LIANG Huiting, WANG Qi.
Down⁃regulation of α2⁃macroglobulin expression activates TGF⁃β/SMADs signaling pathway to induce cisplatin resistance in ovarian cancer
[J]. Chinese Journal of Oncology Prevention and Treatment, 2024, 16(6): 707-714.
|
| [3] |
LONG Yuhao, ZHENG Bohao, ZHOU Shengtao.
Effect of m6A modification on ovarian cancer and its value as a potential therapeutic target
[J]. Chinese Journal of Oncology Prevention and Treatment, 2024, 16(2): 238-242.
|
| [4] |
ZHANG Mengpei, YIN Rutie.
Epithelial ovarian cancer: current status and progress of chemotherapy
[J]. Chinese Journal of Oncology Prevention and Treatment, 2023, 15(5): 477-484.
|
| [5] |
CHEN Xiaoqi, ZHAO Bingbing, LI Zhuang, FENG Yanying, YANG Zhijun.
The role and mechanism of piR-hsa-130912 in promoting proliferation,invasion and migration ofepithelial ovarian cancer cells
[J]. Chinese Journal of Oncology Prevention and Treatment, 2023, 15(3): 263-271.
|
| [6] |
ZHOU Zihan, LI Qiulin, YU Jiahua, RONG Minhua, CAO Ji, GE Lianying, TANG Weizhong, YU Hongping.
Epidemiological characteristics and disease burden of cancer in Guangxi cancer registration areas， 2017
[J]. Chinese Journal of Oncology Prevention and Treatment, 2022, 14(3): 264-273.
|
| [7] |
CHEN Chaomei, XI Min, SHI Xiu, WANG Fang, ZHOU Jinhua.
Effect of silencing G6PD on cisplatin sensitivity of ovarian cancer cells and its mechanism
[J]. Chinese Journal of Oncology Prevention and Treatment, 2022, 14(3): 274-280.
|
| [8] |
WU Shili, XU Li, ZHANG Yan.
A prospective study of the effect of lymph node dissection on the prognosis of patients with early ovarian cancer
[J]. Chinese Journal of Oncology Prevention and Treatment, 2022, 14(3): 305-309.
|
| [9] |
WANG Xingguo, XU Zhiyang, LIU Shujuan, XING jinliang.
Research progress of tumor markers in the diagnosis of ovarian cancer
[J]. Chinese Journal of Oncology Prevention and Treatment, 2022, 14(1): 111-116.
|
| [10] |
HAO Lingji, ZHANG Zhe, DONG Xunhu.
Construction and validation of a novel immune-related prognostic signature of ovarian cancer
[J]. Chinese Journal of Oncology Prevention and Treatment, 2021, 13(5): 511-517.
|
| [11] |
HU Mingmiao, CHEN Mengjie, LIANG Yuejuan, WANG He.
Analysis of factors influencing pregnancy after fertility sparing treatment for malignant ovarian germ cell tumors
[J]. Chinese Journal of Oncology Prevention and Treatment, 2021, 13(5): 539-543.
|
| [12] |
WANG Mengxin, GAO Tian, LIU Yang, LIU Shujuan, XING Jinliang .
Research progress of mitochondrial DNA mutation detection in clinical diagnosis and treatment of ovarian cancer
[J]. Chinese Journal of Oncology Prevention and Treatment, 2020, 12(3): 268-273.
|
| [13] |
Gynecological Oncology Group, the Invasive and Noninvasive Medical Committee of Chinese Medical Doctor .
Low-grade serous ovarian cancer：Chinese expert consensus（2020 Version）
[J]. Chinese Journal of Oncology Prevention and Treatment, 2020, 12(2): 117-125.
|
| [14] |
BAI Xiangyu, CAO Shanshan, YANG Shirong, GAO Tian, CHEN Yanqin, BAO Dengke.
Effect of MCUR1 expression on the growth of ovarian cancer cells and its mechanism
[J]. Chinese Journal of Oncology Prevention and Treatment, 2020, 12(1): 21-27.
|
| [15] |
QIU Liyu, LI Ni, WU Guili.
Quality of life in advanced ovarian cancer patients undergoing hyperthermic intraperitoneal chemotherapy
[J]. Chinese Journal of Oncology Prevention and Treatment, 2019, 11(5): 430-433.
|
